KE / Domain	AOP entity (KE/KER)	Input (manipulation / sample)	Method / Assay (SOP notes)	Output / Measurement	Interpretation / Context fields to capture	Exemplar peer-reviewed manuscripts	Protocol / SOP notes (attach)	S&T considerations (ontology / mapping)
Sputum inflammatory cell profiles and microbiome	Organism-level outcome; relationship to airway inflammation and oxidative stress; potential link to lung function decline	Human sputum samples from healthy and diseased subjects (e.g., COPD, asthma); bronchoalveolar lavage fluid (BALF) samples	Sputum collection and processing for cell differential counts. Flow cytometry or microscopy for inflammatory cell quantification (neutrophils, eosinophils, macrophages, lymphocytes). 16S rRNA sequencing for microbiome analysis. Cytokine and chemokine measurements (multiplex assays or ELISA).	Inflammatory cell counts and percentages (neutrophils %, eosinophils %, macrophages %, lymphocytes %); Microbiome composition (alpha diversity, beta diversity, taxonomic abundance); Cytokine/chemokine levels (IL-6, IL-8, TNF-α, etc.); Correlation between cellular inflammation and microbiome	Subject demographics (age, sex, smoking status); disease diagnosis and severity; medication use; sputum collection method (spontaneous vs induced); sample processing time; cell viability; flow cytometry panels and gating strategy; sequencing platform and depth; bioinformatics pipeline version; statistical analysis methods	Cobos-Uribe et al. (2025). Human sputum microbiome composition and sputum inflammatory cell profiles are altered with [condition].	Include sputum induction protocol (if applicable), sample processing workflow, cell counting method, flow cytometry antibody panels, DNA extraction protocol, 16S sequencing primers and protocol, bioinformatics pipeline, quality control criteria	Biolink: MeasurementProcess; OBI: flow cytometry assay, 16S rRNA gene sequencing assay; Mapping: inflammatory cell quantification, microbiome analysis; ENVO: sputum sample; Clinical biomarker potential
BALF/Sputum biomarker analysis	Organism-level outcome; biomarkers of airway inflammation and disease progression	Bronchoalveolar lavage fluid (BALF) or sputum samples from clinical subjects	Sample collection via bronchoscopy (BALF) or sputum induction. Biochemical analysis for protein content, inflammatory markers, oxidative stress markers. Proteomic or metabolomic profiling. Cell-free DNA analysis. Standardized collection and processing protocols.	Protein concentration; Inflammatory marker levels (cytokines, chemokines); Oxidative stress markers (malondialdehyde, 8-isoprostane); Cell counts and differentials; Proteomic/metabolomic signatures	Subject characteristics (age, sex, disease state); bronchoscopy protocol; lavage volume and recovery; sputum induction method; sample processing time and temperature; storage conditions; assay platforms; normalization method (total protein, cell count, volume); batch effects; quality control samples	Nalesnik et al. (2025). [Title from PDF - BALF/Sputum analysis]	Document collection procedure (bronchoscopy or sputum induction), lavage protocol, sample handling and storage, assay-specific protocols (ELISA, mass spectrometry), normalization approach, quality control acceptance criteria	Biolink: MeasurementProcess; OBI: clinical biomarker assay; Mapping: airway inflammation measurement; ENVO: BALF, sputum; Clinical translation for disease monitoring
Mucociliary clearance and mucus properties (related to sputum)	Supports understanding of mucus transport and clearance; relationship to sputum production	In vivo intranasal μOCT imaging; ex vivo airway tissue	Micro-Optical Coherence Tomography (μOCT) for visualizing mucus layer, measuring mucociliary transport rate, and assessing airway surface properties. Non-invasive in vivo imaging. Provides microstructural information about mucus and mucociliary clearance that relates to sputum production capacity.	Mucociliary transport rate (mm/min); Mucus layer thickness; ASL depth (µm); Ciliary beat frequency (Hz); Functional assessment of clearance mechanisms	Subject characteristics; disease state (CF, healthy); anatomical location; environmental conditions; imaging parameters; analysis algorithm; correlation with clinical mucus/sputum production	Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, et al. (2019). Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies. Sci Transl Med. 11(504).	Include μOCT imaging protocol, mucus visualization methods, transport rate calculation, correlation with clinical assessments of mucus production or sputum characteristics	Biolink: MeasurementProcess; OBI: optical coherence tomography assay; Mapping: mucociliary clearance function; Relationship to sputum production and clearance capacity
